Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10

NCT01148524 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

817

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Disease
Meningococcal Meningitis

Interventions

BIOLOGICAL: No Vaccine
BIOLOGICAL: rMenB+OMV-NZ

Sponsor

Novartis Vaccines